Incidence, extent and distribution pattern of delayed cerebral infarction in patients with non-traumatic subarachnoid hemorrhage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005486

Enrollment

850

Registered

2013-12-18

Start date

2013-10-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I60 I63

Interventions

Group 1: Arm 1 - We retrospectively review data from patients admitted to the University hospital of Freiburg with non-traumatic SAH between January 1st 2005 and December 31st 2012. Only patients admi

- Presence of cardio-vascular risk factors (CVRF) at SAH patients: arterial hypertension, cigarette smoking, diabetes mellitus, obesity and previous cardiovascular diseases (coronary artery disease, a

- Clinical grade at discharge, as well as at 3-6 months and 6-12 months after SAH according to modified Rankin scale (mRS)

- Use of antiplatelet agents and other anti-thrombotic drugs (Aspirine, Clopidogrel, Heparin, Abciximab etc.) before onset of SAH, during aneurysm treatment and in the post-treatment phase

- Presence of clinical vasospasm on TCD: according to the guidelines, absolute mean flow velocities (MFV) > 160 cm/s for anterior circulation were deemed as suspicious for clinical vasospasm

- Occurrence of DIND, dichotomized into “reversible deficit” (RIND) and “fixed deficit” (FIND)

- Common laboratory values: hemo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-traumatic subarachnoid hemorrhage

Exclusion criteria

Exclusion criteria: - Beginn of desease earlier than 48 hours before admittion; - treatment in other hospital

Design outcomes

Primary

Measure	Time frame
Incidence, severity and distribution pattern of cerebral infarctions in correlation with: - demographic (age, gender), clinical (Hunt&Hess Grade) and radiological (blood amount according to Fisher-Score, presence of intracerebral/intraventricular hemorrhage) data; - anatomical features of vascular status, evaluated from initial/diagnostic angiography (stenosis, vascular hypo-/aplasia, anatomical variations, arteriosclerosis, macroangiopathy, fibro-muscular dysplasia, early vasospasm etc.), localisation and size of aneurysms; - treatment modality; - anti-coagulation therapy (aspirine, clopidogrel, heparine, ReoPro etc.); - presence of TCD vasospasms; - occurence of delayed neurological deficits: RIND ("reversible deficit") and FIND ("fixed deficit") - labaratory parameters like hemoglobin, hematocrit, glucose, thrombocytes, base excess, lactate, pH, electrolytes, inflammation mediators etc.; - invasive treatment of vasospasm with means of intra-arterial spasmolysis and angioplasty; - treatment complications; - cardio-vascular risk factors (CVRF) like hypertension, smoking history, diabetes history, obesity and cardial pre-morbidity; - early- ("at discharging") and late- ("3, 6, 12 Mo. after Stroke") Outcome.	—

Measure

Time frame

Incidence, severity and distribution pattern of cerebral infarctions in correlation with: - demographic (age, gender), clinical (Hunt&Hess Grade) and radiological (blood amount according to Fisher-Score, presence of intracerebral/intraventricular hemorrhage) data; - anatomical features of vascular status, evaluated from initial/diagnostic angiography (stenosis, vascular hypo-/aplasia, anatomical variations, arteriosclerosis, macroangiopathy, fibro-muscular dysplasia, early vasospasm etc.), localisation and size of aneurysms; - treatment modality; - anti-coagulation therapy (aspirine, clopidogrel, heparine, ReoPro etc.); - presence of TCD vasospasms; - occurence of delayed neurological deficits: RIND ("reversible deficit") and FIND ("fixed deficit") - labaratory parameters like hemoglobin, hematocrit, glucose, thrombocytes, base excess, lactate, pH, electrolytes, inflammation mediators etc.; - invasive treatment of vasospasm with means of intra-arterial spasmolysis and angioplasty; - treatment complications; - cardio-vascular risk factors (CVRF) like hypertension, smoking history, diabetes history, obesity and cardial pre-morbidity; - early- ("at discharging") and late- ("3, 6, 12 Mo. after Stroke") Outcome.

—

Secondary

Measure	Time frame
- Value of infarct scoring system for prediction of early and late outcome of SAH patients; - management of raised intracranial pressure among SAH patients: need for external liquor drain / additional conservative and surgical treatment; - impact of complications on outcome; - Diabetes insipidus and SAH; - Meningitis and SAH; - Epilepsy and SAH; - Shunt-dependency and SAH.	—

Countries

Germany

Contacts

Public ContactRamazan Jabbarli

Neurochirurgie, UKL Freiburg

radjapost@hotmail.com01756370955

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 28, 2026